Nafazatrom as a lipoxygenase inhibitor
AssigneeBayer Aktiengesellschaft
InventorsMithat Mardin, Wolf-Dieter Busse, Friedrich Hoffmeister, Friedel Seuter, Elisabeth Perzborn, Klaus Schlossmann, Dieter Mayer, Volker Fiedler
Life of this patent
Estimating the term…
Abstract
A method of inhibiting lipoxygenase in a patient, for the prophylaxis and/or treatment of ischaemias and disorders in cardiac rhythm and of rheumatic, allergic and asthmatic diseases, oedemas, pulmonary embolisms, pulmonary hypertension, oxygen intoxications and ulcerations which comprises administering to such patient an effective amount of nafazatrom.
Claims1
A method of inhibiting lipoxygenase in a patient, for the prophylaxis and/or treatment of disorders in cardiac rhythm, which comprises administering to such patient an effective amount of nafazatrom.
Dependencies are inferred from the claim text.